Burning Rock Biotech Ltd
brbiotech.comWhat Do They Do?
Sells genomic tests and related services that help physicians select cancer treatments, monitor cancer after treatment, and detect cancers early for patients, hospitals, and pharmaceutical companies.
20-F for FY2025, filed Apr 28, 2026We offer a broad spectrum of NGS-based products. Our NGS-based cancer therapy selection test products are used to assist physicians in…View ↗
In addition to our NGS-based cancer therapy selection tests, we are also investing in our development of early cancer detection tests.…View ↗
The disease monitoring and surveillance utility of ctDNA test had been drawing extensive academic and clinical interest in recent years.…View ↗
The Group provides pharma research and development services, primarily cancer therapy selection tests services, companion diagnostics…View ↗
Who Are Their Customers?
Individual patients buy cancer therapy tests through the central laboratory, which receives samples from hospitals; hospitals buy reagent kits for in-house testing, and pharmaceutical companies and hospitals hire the company for cancer research and companion-diagnostic services.
20-F for FY2025, filed Apr 28, 2026Revenue from central laboratory business is primarily generated through the sales of the Group’s cancer therapy selection test, to…View ↗
Central laboratory model. Since 2014, we have offered our cancer therapy selection tests under a central laboratory model. Under this…View ↗
In-hospital model. In China, cancer patients typically go to top oncology hospitals for cancer treatment. These hospitals generally prefer…View ↗
The Group provides pharma research and development services, primarily cancer therapy selection tests services, companion diagnostics…View ↗
How Are They Changing?
Greater in-hospital focus
The earlier report framed central-lab testing as the larger business and in-hospital kits as smaller; the latest report describes a strategic move toward in-hospital laboratories, with central-lab revenue expected to be steadier.
20-F for FY2022, filed Apr 20, 2023 20-F for FY2025, filed Apr 28, 2026Central laboratory model: Our central laboratory processes cancer patients’ tissue and liquid biopsy samples delivered to us from hospitals…View ↗
Who Do They Compete With?
Competes with AmoyDx, BGI, and Geneseeq
20-F for FY2025, filed Apr 28, 2026We are China’s number one NGS-based cancer therapy selection company. China’s cancer genotyping industry is highly competitive. Our major…View ↗
Loading...
